STOCK TITAN
  1. Home
  2. News
  3. MDGL

Madrigal Pharmaceuticals Inc - MDGL STOCK NEWS

Welcome to our dedicated news page for Madrigal Pharmaceuticals (Ticker: MDGL), a resource for investors and traders seeking the latest updates and insights on Madrigal Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Madrigal Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Madrigal Pharmaceuticals's position in the market.

News
Madrigal Statement on the Passing of Dr. Stephen Harrison
Rhea-AI Summary
Madrigal expresses deep sorrow over the passing of Dr. Stephen Harrison, a pivotal figure in NASH research. Dr. Harrison's dedication to improving the lives of NASH patients and his collaborative approach with various stakeholders leaves a lasting impact on the field of hepatology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.02%
Tags
none
-
News
Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024
Rhea-AI Summary
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) will release its first-quarter 2024 financial results on May 7, 2024. The management will host a live webcast to review the financial and operating results at 8 a.m. Eastern Time. Participants can access the webcast on the company's Investor Relations section of the website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.29%
Tags
earnings
-
News
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Madrigal Pharmaceuticals, Inc. granted equity awards to 7 new employees under Nasdaq Listing Rule 5635(c)(4), with options to purchase 1,979 shares of common stock and 4,078 time-based restricted stock units. The options have an exercise price of $231.37 per share and vest over time, while the restricted stock units vest in increments over four years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.99%
Tags
none
News
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis
Rhea-AI Summary
Madrigal Pharmaceuticals, Inc. announces FDA approval of Rezdiffra for NASH treatment, marking a significant milestone in the NASH community. Rezdiffra is now available in the U.S. for adults with noncirrhotic NASH with moderate to advanced liver fibrosis. The medication does not require a biopsy for diagnosis, a patient-centric approach applauded by healthcare advocates. The first patients have started receiving Rezdiffra, showcasing a pivotal moment for Madrigal and NASH patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
none
-
News
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Madrigal Pharmaceuticals, Inc. (MDGL) granted equity awards to 30 new employees under its 2023 Inducement Plan. The awards include options to purchase 1,813 shares and 12,709 restricted stock units. The options have an exercise price of $255.74 per share and vest over time. The restricted stock units vest in increments over four years, subject to continued employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.54%
Tags
none
-
News
Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering
Rhea-AI Summary
Madrigal Pharmaceuticals, Inc. announces a public offering of 750,000 shares of common stock and pre-funded warrants, increasing the size by $100 million to approximately $600 million in gross proceeds. The company plans to use the net proceeds for commercial activities related to the launch of Rezdiffra™ (resmetirom) in the U.S. and for general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.2%
Tags
offering
News
Madrigal Pharmaceuticals Announces Proposed Public Offering
Rhea-AI Summary
Madrigal Pharmaceuticals, Inc. initiates a public offering of $500 million in shares of common stock and pre-funded warrants to support commercial activities for Rezdiffra™ (resmetirom) launch in the U.S. The offering aims to drive research, development, clinical trials, acquisitions, and capital expenditures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.2%
Tags
offering
-
News
Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis
Rhea-AI Summary
Madrigal Pharmaceuticals, Inc. (MDGL) receives accelerated FDA approval for Rezdiffra, the first medication for NASH with moderate to advanced liver fibrosis. The approval is based on Phase 3 data showing significant improvement in liver fibrosis and NASH resolution. Rezdiffra is a once-daily oral medication that targets key causes of NASH. The prescribing information does not require a liver biopsy. The MAESTRO-NASH trial demonstrated positive results, with Rezdiffra showing improvement in fibrosis and NASH resolution. The medication is expected to be available in the U.S. in April.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11%
Tags
fda approval
-
News
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Madrigal Pharmaceuticals, Inc. granted equity awards to its new CFO and 39 other employees under the 2023 Inducement Plan. The awards include options, restricted stock units, and performance stock units, subject to vesting conditions. The CFO received options to purchase 13,353 shares, while other employees received options to purchase 853 shares. All options have an exercise price of $251.63 per share and vest over time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.47%
Tags
none
News
Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis
Rhea-AI Summary
Madrigal Pharmaceuticals announces the submission of Marketing Authorization Application for resmetirom for NASH treatment, supported by positive Phase 3 trial results. Resmetirom aims to target key causes of NASH and has shown efficacy in reducing fibrosis and resolving NASH. The drug is under review with the FDA and EMA, with potential approval in Europe and the US.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.78%
Tags
none
Stock MDGL logo
Madrigal Pharmaceuticals Inc

Nasdaq:MDGL

MDGL Rankings

#1336 Ranked by Market Cap
#248 Ranked by Stock Gains
N/A Ranked by Dividends

MDGL Stock Data

4.96B
12.78M
9.24%
94.65%
16.3%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Fort Washington

About MDGL

madrigal pharmaceuticals inc. is a biotechnology company based out of calle laguna del marquesado nª 19, nave 16 edificio adriana 1ª planta, polígono industrial la resina (villaverde), madrid, community of madrid, spain.